Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Thermo Fisher Scientific has strong growth prospects due to easing COVID-19 headwinds, improving Chinese and biotech markets, ...

Get a crash course on Windows Server 2025, brush up on your Entra know-how, find out what's up with AI agents, and learn how ...